By allowing insurance companies to price plans based on biometric data (blood pressure, fitness), you create powerful financial incentives for people to improve their health. This moves beyond abstract advice and makes diet and exercise a direct factor in personal finance, driving real behavioral change.

Despite processing 15 million clinical charts, Datycs doesn't use this data for model training. Their agreements explicitly respect that data belongs to the patient and the client—an ethical choice that prevents them from building large, aggregated language models from customer data.

Because their platform generates more high-potential drug targets than they can pursue internally, the company frames partnerships with large pharmaceutical firms as an ethical imperative. This approach ensures novel findings don't languish, allowing them to become life-saving drugs while triggering revenue sharing for their community partners.

Paying bone marrow donors—a practice often avoided due to ethical concerns—can be highly effective. An independent campaign offering significant compensation led to 15,000 new sign-ups from a targeted community. When the payment is high, it can be framed as a reciprocal gift rather than exploitation, overcoming ethical hurdles.

Variant Bio's advantage lies in its ethical approach to partnering with indigenous communities. This model, which includes co-designing studies and robust benefit sharing, grants them exclusive access to unique genetic datasets that competitors, focused on traditional data sources, cannot obtain.

Financial returns from a drug discovery are shared equally among all participating communities, not just the one whose data led to the breakthrough. This non-transactional model creates a collective partnership, decoupling a community's specific data contribution from its eventual reward and fostering broader collaboration.

In the rare disease space, success hinges on deep patient community engagement. Smaller, nimbler biotechs often excel at creating these essential personal ties, giving them a significant advantage over larger pharmaceutical companies.

Instead of relying solely on traditional LPs, Vi Ventures actively brings in families affected by autoimmune diseases as for-profit investors. This model creates a community of highly motivated stakeholders, fostering accountability and a direct connection to the patient experience, while still maintaining market-rate return objectives.

Public skepticism towards AI is fueled by the perception that wealth is being concentrated by a select few. A radical solution is to grant a broad base of people direct ownership stakes in foundational model companies, aligning incentives and shifting the narrative to one of shared investment in the future.